COMPANY
Opsin Biotherapeutics Inc.
Funding and NIH signals
- NIH award NIH awarded $1.11M (SBIR Phase II 2R44NS132623-02, competing renewal, notice Sep 21, 2026). NIH RePORTER 2R44NS132623-02 (Sep 21, 2026)
Evidence (1 event)
- Sep 21, 2026 · NIH RePORTER 2R44NS132623-02
Organization: OPSIN BIOTHERAPEUTICS INC.; City/State: BEDFORD, TX; Project number: 2R44NS132623-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-21; FY total cost (award amount): 1113701; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Optogenetic Neuromodulation for Chronic Pain; Organization type: Domestic For-Profits
- Sep 21, 2026 · NIH RePORTER 2R44NS132623-02
Timeline
- Grant Government grant — SBIR: $1.11M (annual award, as published), announced Sep 21, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Funding
- Government grant — SBIR: $1.11M (annual award, as published), announced Sep 21, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
NIH awards 1
- NIH award 1R43NS132623-01 FY2023: $327,864 awarded for that fiscal year; activity R43 (SBIR); PI NARCISSE, DARRYL J; recipient as written: OPSIN BIOTHERAPEUTICS INC., BEDFORD, TX. Optogenetic Pain Modulator for non-o source ↗